
|Videos|May 1, 2019
Assessing the Role of 21-Gene Assays in Breast Cancer
Author(s)John H. Ward, MD
John H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.
Advertisement
John H. Ward, MD, Margaret A. Amundsen Endowed Professor of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.
Patients who have a low 21-gene recurrence score can be spared chemotherapy. It is predicted that 46% of women with breast cancer can forego chemotherapy, according to Ward.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5

































